ATPC and FORMEDIC Technologies Announce Strategic Collaboration to Launch LEGA, a Revolutionary Respiratory Care Device

Rhea-AI Summary

NASDAQ-listed AGAPE ATP (ATPC) has announced a strategic collaboration with FORMEDIC Technologies to launch LEGA, an electronic chest percussion device for respiratory care. This partnership aims to address the growing demand for advanced respiratory solutions in a market estimated to reach USD 25.95 billion in 2024 and USD 49.84 billion by 2031.

LEGA, FORMEDIC's flagship product, assists patients with chronic obstructive pulmonary diseases (COPD), pneumonia, bronchiectasis, and other lung-related conditions. The device has already gained traction with nearly 2,000 units used in major hospitals and rehabilitation centres globally.

This collaboration allows ATPC to diversify its wellness portfolio and leverage FORMEDIC's expertise in healthcare technology. The partnership will focus on continuous R&D efforts and joint marketing strategies to position LEGA as a leading respiratory care solution globally.

Positive

• Strategic entry into the fast-growing respiratory care market, estimated at USD 25.95 billion in 2024
• Diversification of ATPC's wellness portfolio with a proven medical device
• Leveraging FORMEDIC's expertise in healthcare technology and R&D capabilities
• Expansion into healthcare technology, an area with high growth potential
• Potential to enhance shareholder value through market expansion and innovation

Negative

• None.

Insights

Medical Technology Analyst

This strategic collaboration between ATPC and FORMEDIC Technologies to launch LEGA, an electronic chest percussion device, represents a significant move into the rapidly growing respiratory care market. With the global respiratory care market projected to reach $49.84 billion by 2031, this partnership positions ATPC to capitalize on increasing demand for advanced respiratory solutions.

The LEGA device addresses critical needs in managing conditions like COPD, pneumonia and bronchiectasis, with nearly 2,000 units already in use globally. This proven track record enhances ATPC's credibility in the medical device sector. The collaboration also opens doors for continuous R&D and innovation, potentially leading to a suite of respiratory care products.

For investors, this move signifies ATPC's strategic diversification into healthcare technology, a high-growth sector. It could lead to new revenue streams and market expansion opportunities, particularly in emerging markets with rising respiratory disease prevalence. However, investors should monitor regulatory approvals, market adoption rates and competition in this space to gauge long-term success.

Financial Analyst

This collaboration marks a strategic pivot for ATPC, diversifying its portfolio beyond wellness into medical devices. The respiratory care market's projected growth from $25.95 billion in 2024 to $49.84 billion by 2031 presents a substantial revenue opportunity. However, investors should consider the capital requirements for scaling production, marketing and distribution of LEGA.

ATPC's current market cap of $7,514,284 suggests it's a small-cap company. This move could significantly impact its financial profile, potentially leading to revenue growth but also increased R&D and marketing expenses. The partnership model with FORMEDIC may help mitigate some risks and capital requirements.

Investors should watch for updates on sales projections, profit margins for LEGA and any changes in ATPC's financial guidance. The success of this venture could lead to a re-evaluation of ATPC's valuation, particularly if it can capture a meaningful share of the growing respiratory care market.

Innovative Collaboration Brings Advanced Respiratory Solutions to a Global Market

KUALA LUMPUR, MALAYSIA / ACCESSWIRE / September 30, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), is proud to announce a strategic collaboration with FORMEDIC Technologies Sdn. Bhd. ("FORMEDIC Technologies") to introduce LEGA, an electronic chest percussion device for respiratory care. This partnership marks a major advancement in respiratory health, as the two companies combine their strengths to address the growing demand for advanced respiratory solutions.

LEGA, FORMEDIC's flagship product, assists patients with chronic obstructive pulmonary diseases ("COPD"), pneumonia, bronchiectasis, and other lung-related conditions by providing critical support for airway clearance and secretion management. LEGA helps to manage secretion drainage and airway clearance, offering much-needed relief to patients both adults and children, facing respiratory difficulties in both hospital and home care settings. This device has already gained significant traction in the medical field, with close to 2,000 units used in major hospitals and rehabilitation centres in Malaysia and globally.

For ATPC, this collaboration brings opportunities in the fast-growing respiratory care market, estimated to reach USD 25.95 billion in 2024, with a strong growth trajectory, estimating it to hit USD 49.84 billion by 2031¹. As respiratory diseases continue to rise globally, this partnership positions ATPC to capitalise on the increasing demand for advanced respiratory solutions, as well as diversifying its wellness portfolio with a proven medical device.

¹Coherent Market Insight, Respiratory Care Market Size and Trends (2024-2031)

L-R: Prof Dato' Sri Dr How Kok Choong, Founder and Global Group CEO of ATPC and Ng Zim Guan, Director of FORMEDIC Technologies Sdn. Bhd (link)

Prof Dato' Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC, said, "The partnership allows ATPC to leverage FORMEDIC's expertise in healthcare technology and clinical applications and research and development capabilities, aligning with ATPC's long-term vision of building a holistic wellness ecosystem that encompasses both preventive and curative solutions.

This is an opportunity for us to address a critical global health need. With LEGA, we are expanding our operations into healthcare technology, an area with immense growth potential. We look forward to continue delivering value through innovation and strategic diversification, and at the same time, accelerate ATPC's growth and market reach, enhancing shareholder value."

Ng Zim Guan, Director of FORMEDIC Technologies, added, "LEGA is the culmination of years of research and clinical trials, and our partnership with ATPC allows us to reach more patients globally. We aim to redefine respiratory care with cutting-edge solutions and LEGA's non-invasive, electronic chest percussion technology has already proven to be a vital tool in improving respiratory health. Partnering with ATPC allows us to further scale this technology and reach more patients in need."

In addition to improving lung health, the collaboration will focus on continuous R&D efforts to explore innovations and develop solutions to improve patient outcomes. ATPC and FORMEDIC will jointly develop marketing strategies to position LEGA as the leading respiratory care solution, ensuring greater accessibility to hospitals, rehabilitation centres, and home users globally.

###

About AGAPE ATP Corporation

Agape ATP Corporation (ATPC) is dedicated to enhancing the quality of life and promoting sustainable development. With a strong foundation built on two core business pillars, ATPC specialises in the provision of health and wellness products that caters to the diverse needs of its customers, ensuring their well-being and vitality. Additionally, APTC delivers comprehensive energy-saving solutions that empower companies to drive sustainability initiatives, reduce energy consumption, and achieve their sustainability goals.

For more information, visit www.agapeatpgroup.com.

Issued By: Swan Consultancy Sdn. Bhd. on behalf of Agape ATP Corporation

For more information, please contact:

Jazzmin Wan
Tel: +60 17-289 4110
Email: j.wan@swanconsultancy.biz

Mandy Tan
Tel: +60 16-477 2257
Email: m.tan@swanconsultancy.biz

FORWARD-LOOKING STATEMENT

Certain statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, those related to the anticipated benefits and outcomes of the collaboration between ATPC and FORMEDIC Technologies, the expected impact of LEGA on the respiratory care market, and the overall growth potential in the health and wellness sectors. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company's ability to execute its strategies, manage growth, and maintain its corporate culture; the Company's future business development, financial conditions, and results of operations; expectations regarding demand for and market acceptance of our products and services; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Malaysia and the international markets the Company plans to serve, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and AGAPE ATP Corporation specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

SOURCE: Agape ATP Corporation

View the original press release on accesswire.com

FAQ

What is LEGA and how does it benefit respiratory patients?

LEGA is an electronic chest percussion device that assists patients with COPD, pneumonia, bronchiectasis, and other lung-related conditions. It supports airway clearance and secretion management, providing relief to both adult and pediatric patients in hospital and home care settings.

How many LEGA units are currently in use globally?

Nearly 2,000 LEGA units are currently used in major hospitals and rehabilitation centers globally.

What is the projected market size for respiratory care by 2031?

The respiratory care market is projected to reach USD 49.84 billion by 2031, according to the press release.

How does the ATPC-FORMEDIC collaboration benefit ATPC's business strategy?

The collaboration allows ATPC to diversify its wellness portfolio, enter the growing respiratory care market, and leverage FORMEDIC's expertise in healthcare technology. This aligns with ATPC's vision of building a holistic wellness ecosystem and potentially enhances shareholder value.

What are the future plans for ATPC and FORMEDIC regarding LEGA?

ATPC and FORMEDIC plan to focus on continuous R&D efforts to explore innovations and develop solutions to improve patient outcomes. They will also jointly develop marketing strategies to position LEGA as the leading respiratory care solution globally.